Despite the absence of large-scale studies specifically involving KTRs, our meta-analysis reveals that SGLT-2 inhibitors significantly reduce mortality and cardiovascular disease in this unique population, offering a compelling new therapeutic avenue to address their elevated cardiovascular risk. This evidence concerns the gene SLC5A2 and cardiovascular disorder.